SecBot SecBot
SECBOTREPLAY Home › Report › DNTH

DNTH · Dianthus Therapeutics initiated the Phase 3 EMERGE trial of…

Dianthus Therapeutics, Inc. · PRESS-RELEASE filed Jun 29, 2026 at 07:00 ET

At the news

BULLISHIMPACT 5/10

PRESS-RELEASE filed Jun 29, 2026 at 07:00 ET

Dianthus Therapeutics initiated the Phase 3 EMERGE trial of claseprubart in generalized Myasthenia Gravis, building on positive Phase 2 results. Top-line data expected in 2H'28; the stock may see modest positive momentum from trial advancement but major catalysts are distant.

  • Phase 3 EMERGE trial initiated in ~195 AChR+ gMG patients with claseprubart 300mg Q2W or Q4W
  • Primary endpoint: change from baseline in MG-ADL; top-line results expected 2H'28
  • Claseprubart granted Orphan Drug Designation by FDA for MG in May 2026
  • Phase 2 MaGic trial showed rapid, sustained, statistically significant improvements vs placebo

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access